Nintedanib Zentiva (Nintedanib Esylate)

Nintedanib esylate, the active ingredient in Nintedanib Zentiva, is a tyrosine kinase inhibitor presented as a oral capsule for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used with docetaxel for non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib Zentiva is indicated for fibrotic lung disorders and certain cancers where inhibition of multiple tyrosine kinases is therapeutic.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and may delay worsening. - Non‑small cell lung cancer (in combination with docetaxel): enhances response rates and overall survival in previously treated patients.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may occur early in treatment. - Vomiting: occasional episodes, usually self‑limiting. - Decreased appetite: reduced desire to eat. - Liver enzyme elevation: mild increases in ALT/AST.

Serious or Rare Side Effects: - Severe liver injury: marked elevation of transaminases or hepatitis. - Cardiovascular events: arterial thromboembolism or myocardial infarction. - Gastrointestinal perforation: rare but potentially life‑threatening.

Before initiating Nintedanib, clinicians should consider several safety precautions.

- Liver function monitoring: assess baseline ALT/AST and repeat regularly. - Bleeding risk: avoid in patients with active bleeding or on strong anticoagulants. - Cardiovascular assessment: evaluate history of ischemic heart disease before use. - Gastrointestinal health: monitor for severe diarrhea or abdominal pain. - Pregnancy and lactation: contraindicated in pregnancy (Category D) and not recommended while breastfeeding. - Store at ambient temperature: keep capsule bottles below 25 °C, protect from moisture and light.

Nintedanib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑glycoprotein inhibitors (e.g., itraconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - NSAIDs: increase gastrointestinal adverse events.